Insights from the TIOSPIR Trial

The TIOSPIR^™ trial is one of the largest COPD trials ever conducted and shows a comparable safety and efficacy profile of SPIRIVA^® Respimat^® 2.5 µg (once a day, 2 puffs)* and SPIRIVA^® HandiHaler^® 18 µg

*This is the marketed dose referred to in the NEJM TIOSPIR^™publication as tiotropium Respimat^® 5 µg